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Abstract
Background: Aboriginal and Torres Strait Islander Australians have poorer cancer outcomes than other Australians.
Comparatively little is known of the type and amount of cancer treatment provided to Aboriginal and Torres Strait
Islander people and the consequences for cancer survival. This study quantifies the influence of surgical, systemic
and radiotherapy treatment on risk of cancer death among matched cohorts of cancer cases and, the comparative
exposure of cohorts to these treatments.
Methods: Cancers registered among Aboriginal South Australians in 1990–2010 (N = 777) were matched with
randomly selected non-Indigenous cases by sex, birth and diagnostic year, and primary site, then linked to
administrative cancer treatment for the period from 2months before to 13 months after diagnosis. Competing risk
regression summarised associations of Indigenous status, geographic remoteness, comorbidities, cancer stage and
treatment exposure with risk of cancer death.
Results: Fewer Aboriginal cases had localised disease at diagnosis (37.2% versus 50.2%) and they were less likely to:
experience hospitalisation with cancer diagnosis, unadjusted odds ratio (UOR) = 0.76; 95%CI = 0.59–0.98; have
surgery UOR = 0.65; 95%CI = 0.53–0.80; systemic therapies UOR = 0.64; 95%CI = 0.52–0.78; or radiotherapy, UOR =
0.76; 95%CI = 0.63–0.94. Localised disease carried lower risk of cancer death compared to advanced cases receiving
surgery or systemic therapies, SHR = 0.34; 95%CI = 0.25–0.47 and SHR = 0.35; 95%CI = 0.25–0.48. Advanced disease
and no treatment carried higher risk of cancer death, SHR = 1.82; 95%CI = 1.26–2.63.
Conclusion: The effects of treatment did not differ between Aboriginal and non-Indigenous cohorts. However,
comparatively less exposure to surgical and systemic treatments among Aboriginal cancer cases further
complicated the disadvantages associated with geographic remoteness, advanced stage of disease and co-morbid
conditions at diagnosis and add to disparities in cancer death. System level responses to improving access,
utilisation and quality of effective treatments are needed to improve survival after cancer diagnosis.
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Background
Australia’s Aboriginal and Torres Strait Islander popula-
tion experience higher burden of disease from cancer
compared to other Australians [1–3]. This excess burden
is a function of diagnosis at younger average ages but
lower cancer survival rates [4–7]. The disparities in sur-
vival are significantly influenced by widely reported factors
such as comorbid conditions which pre-exist cancer diag-
nosis [8–10] and cancers often being diagnosed at rela-
tively advanced stages with the cancer having spread to
other tissue or organs [1, 2, 11]. Other disparities occur-
ring after cancer diagnosis also exist. Ethnic disparities in
the treatment of cancer are also implicated and have been
the subject of international research and analysis for de-
cades in the US [12] and other developed countries [13]
for a wide range of primary cancer sites [14–21] and treat-
ment modalities including surgery [14, 15], systemic ther-
apies [16, 18], and radiotherapy [16, 18]. Studies in New
Zealand found that Indigenous people (Maori) received
less surgery for colon [22], breast [23, 24] and prostate
[25] cancers, which increased their risk of cancer death
and even accounted for survival disparities in some ana-
lyses [22, 24].
Australia’s first review of cancer treatments among Abo-
riginal and Torres Strait Islander people reported that
poor survival outcomes were accompanied by lower rates
of cancer hospitalisation [4]. Subsequent analyses within
Australian states and territories, focussing on lung cancer
and using person-linked cancer registry and hospital re-
cords, found surgery was clearly less frequent among Abo-
riginal and Torres Strait Islander people in Western
Australia (WA) [26, 27], New South Wales (NSW) [28],
the Northern Territory (NT) [29] and Queensland [30]. In
Queensland, Aboriginal and Torres Strait Islander people
with head and neck cancers were less like to receive sur-
gery [31], and those with cervical cancer were less likely to
receive optimal treatment [30] than other Australians. Ex-
posure to breast cancer surgery was more equivocal with
no differences reported in Queensland [32], but with
lower odds of surgery reported among Aboriginal women
in NSW [33]. Two matched cohort studies in Queensland
considered cancer treatment more generally [8, 9] and
found Aboriginal and Torres Strait Islander patients were
less likely to receive surgery, chemotherapy and radiother-
apy compared to cases among other Australians for the
same primary sites, similar ages, and diagnostic periods of
time. The observed lesser treatment of cancer was consid-
ered to pose a significant risk to cancer survival in each
study [8, 9, 28, 29, 33].
While hospitals continue to provide most surgical
treatment for cancer, the delivery of some other treat-
ments has changed over time and moved from requiring
hospital admission to outpatient and community set-
tings. To obtain a comprehensive picture, hospital data
can be linked with medical claims data, such as those
from the Australian Pharmaceutical Benefits Scheme
(PBS) and Medicare Benefits Schedule (MBS) [34].
To confirm the continued existence of disparities in can-
cer outcomes for Aboriginal and Torres Strait Islander
people in South Australia (SA), to better determine the rea-
sons for disparities and to inform changes in cancer care,
an extended data system was developed by linking cancer
registry, hospital, PBS and MBS treatment records in a
Cancer Data and Aboriginal Disparities (CanDAD) project
[35]. CanDAD aimed to develop and test an integrated can-
cer monitoring and surveillance system by incorporating
epidemiological and narrative data to advocate and support
health system change [35, 36]. To date CanDAD has de-
scribed the associations between Indigenous status, geo-
graphic remoteness, cancer stage at diagnosis and
comorbid conditions with cancer survival [1, 10].
In this study, we extend those earlier analyses by in-
cluding uptake of cancer treatments. Specifically, we
quantify the effect of, and exposure to, three treatment
modalities: surgery, systemic therapy and radiotherapy
on cancer death among matched population-based co-




Aboriginal health research in South Australia is guided
by a principled approach to research conduct and gov-
ernance by Aboriginal community representatives [37].
The CanDAD project’s governance included a study spe-
cific Aboriginal Community Reference Group [38].
Study design, setting and participants
This study utilised a retrospective matched cohort de-
sign focused on cancer cases diagnosed within the South
Australian population. Situated in southern, central
Australia, South Australia comprises a land area of al-
most one million square kilometres and a resident popu-
lation of 1.7 million, of whom 71% live in the capital’s
metropolitan area [38]. The Aboriginal and Torres Strait
Islander population makes up 2.3% of the population
with one-half living in non-metropolitan areas [38]. All
cancer cases diagnosed among Aboriginal and Torres
Strait Islander people in South Australia during the
period 1990 to 2010 were categorised as such. Of those
777 cases, none were described as Torres Strait Is-
landers, therefore this cohort is referred to as the Abori-
ginal cohort. Each case in the Aboriginal cohort was
matched with a cancer case involving a non-Indigenous
person on the basis of: gender; birth and diagnosis year
[39], and primary cancer site.
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Data sources and measurements
Cancer data were obtained from the South Australian
Cancer Registry (SACR), a population-based registry
coding cancer diagnoses to the International Classifica-
tion of Diseases for Oncology (ICD-O-3) [40] and deaths
to ICD-10. A broad definition of cancer death [41] was
adopted to avoid potential misattribution to other organ
sites and undercounting of deaths [10, 42]. Cancer stage
at diagnosis was summarised using SEER methods [43]
as: localised - confined to tissue of origin; regional - in-
vaded adjacent tissue or regional nodes; distant - spread
to distant lymph nodes or other organs, or to leukaemia
(C42.1); and unknown stage where insufficient staging
data were available.
The identification of Aboriginal and Torres Strait Is-
lander people in administrative health records relies on
self-identification by the individual. As the propensity to
self-report as Aboriginal or Torres Strait Islander can vary
across settings and time [44], it can be a source of mis-
classification bias [45]. We optimised the specificity of
Aboriginal and Torres Strait Islander status by erring to-
wards non-Indigenous status when uncertainty existed
after cross-referencing SACR records against other linked
datasets in the study [39], and following additional hand
searching [35]. Some misclassification of Indigenous status
may have resulted as a consequence of this practice, but
we believe the low proportion of non-Indigenous cases
that would have been misclassified would have had little
effect on comparisons by Indigenous status.
SACR records area of residence categorised as geo-
graphically remote and not-remote (Major Cities and
Inner/Outer Regional areas) using the Accessibility/Re-
moteness Index of Australia [46]. Person-linked hospitali-
sations for cohort cases during the period 1 July 1991 to
30 June 2013; included International Classification of Dis-
eases (ICD-10-AM) [47] coded diagnoses extracted from
the Integrated SA Activity Collection (ISAAC) and Alice
Springs Hospital in the NT [35]. Comorbid health condi-
tions recorded to the time of cancer diagnosis were coded
using the Elixhauser Comorbidity Index (ECI) [10, 48].
An Australian standard classification system [49] ar-
ranges hospital procedures into blocks by level of invasive-
ness from: examination; insertion and removal; incision;
to destruction or excision. We categorised surgery as pro-
cedures of most destruction or excision occurring in hos-
pitalisations 2 months before to 13months after the
SACR recorded month of cancer diagnosis. The second
treatment mode was systemic cancer therapies covering
antineoplastic and immune-modulating agents. These
were determined using hospital records (diagnoses Z511/2
&/or procedure blocks 1920) and person-linked PBS re-
cords after 1 July 2002 (Anatomic Therapeutic Classifica-
tion codes L01, L02 and L03). Radiotherapy notifications
were obtained from: the SACR; hospitalisations (diagnosis
Z510 &/or procedure blocks 1786 to 1799); and person-
linked MBS records (using broad type of service category
K). Further treatment categories were derived where cases
received all three treatment modes, or none of the three
treatments.
Outcomes
Survival time was assessed from cancer diagnosis to can-
cer death, or the close of follow-up at 31 December
2011.
Statistical analysis
Analyses were performed using Stata 14 [50] within the Se-
cure Unified Research Environment [51]. Bivariate associa-
tions between Indigenous status, demographic and cancer
related variables were examined using cross-tabulations and
conditional logistic regression. The latter regression tech-
nique was specifically developed to account for matched de-
signs in analyses focused on binary outcomes (for example,
yes/no to living in remote areas, or yes/no to receiving sur-
gery) [52, 53]. We used it to derive the unadjusted odds ra-
tios for Aboriginal rather than non-Indigenous cohort cases
being included in a particular category of socio-
demographic and clinical variables. Associations within each
treatment mode were also cross-tabulated and the p-values
of Pearson’s Chi-Square Test reported. The adjusted odds of
receiving treatment modalities were concurrently assessed
by Indigenous status and localised/non-localised stage at
diagnosis using conditional logistic regression analyses to
appropriately account for the matched design.
Multivariable analysis of the risk of cancer death is re-
ported using sub-hazard ratio (SHR) estimates. We in-
cluded all cohort cases in each model and adjusted for
the competing risk of non-cancer mortality in a manner
consistent with Fine and Gray’s approach [54] by using
Stata’s stcrprep with stcox. Baseline Model 1 was adapted
from our previously published regression models [10]
with interaction terms for Indigenous status as exposure
variable and geographic remoteness as covariate, to-
gether with comorbidity (Elixhauser) category and stage
at diagnosis as moderators. Having found interactions
between stage at diagnosis and treatment effects in each
treatment modality, we categorised all cohort cases into
one of three mutually exclusive groups for reporting and
easy interpretation. These categories were: local stage at
diagnosis with/without the relevant treatment modality;
not local stage but receiving treatment; and, not local
stage but not receiving treatment. Model 2 reports stage
at diagnosis with and without surgical treatment. Models
3 (systemic therapy); 4 (radiotherapy); 5 (cases receiving
all three treatment modes); and 6 (none of the three
treatment modes) were similarly reported. Model 7
regrouped treatment/stage at diagnosis groupings and
further considered the combined effects of surgery,
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systemic and radiotherapies by stage at diagnosis. Each
model’s parsimony and fit to the cohort data were con-
sidered using Bayesian Information Criterion (BIC) sta-
tistics [55]. The sensitivity of results were assessed by
confining cases to those with hospitalisations with prin-
cipal diagnoses of cancer. All Models were assessed to
ensure adherence to the proportional hazards assump-
tion using Schoenfeld residuals [56].
Results
The Aboriginal (N = 777) and matched non-Indigenous
cancer cohorts were equivalent by matching variables
(that is: year of birth; sex; year of diagnosis; and, primary
cancer site). Hospital, MBS and PBS records were linked
for 94.6, 93.4 and 68.9% of cohort cases respectively.
Aboriginal cases were less often linked to MBS and PBS
records than matched non-Indigenous cases, χ2(2) = 35.3
p < 0.001 and χ2(2) = 63.2 p < 0.001 respectively (Fig. 1).
However, linkage of records of Aboriginal cohort cases
improved over time for example, from 81% for PBS re-
cords in the period 2002 to 2006 to 90% from 2007.
The contemporary population setting of cancer in SA
[1] and cohort differences are more fully detailed else-
where [1, 10] but in summary, Aboriginal cases were
more likely to live in geographically remote areas, have
more comorbid conditions and more advanced cancer
stage at diagnosis (Table 1). Aboriginal cases also had
less likelihood of hospitalisation with a principal diagno-
sis of cancer in the treatment period, OR (unadjusted) =
0.76; 95%CI = 0.59–0.98 and consistently lower odds of
receiving surgery, systemic therapy or radiotherapy, or
all three treatment modalities. Conversely, Aboriginal
cases were more likely to have none of the three treat-
ment modes recorded, OR (unadjusted) = 1.87; 95%CI =
1.44–2.43.
Table 2 further describes the distribution of person,
area of residence and clinical characteristics receiving
each treatment mode within each cohort. In both co-
horts, older age was associated with relatively fewer
cases receiving all three treatments (that is surgery and
systemic and radiotherapy) while it was reciprocally as-
sociated with increased numbers receiving none of the
three treatments. Cases not having surgery or radiother-
apies were relatively more common when disease stage
at diagnosis was distant, unstageable or undefined. Other
statistically significant differences within the Aboriginal
cohort compared to non-Aboriginal included less sur-
gery among older cases, more reports of radiotherapy
among distant/unstageable cases and increased reports
of no treatment among Aboriginal males and those liv-
ing in areas of most disadvantage or geographic remote-
ness. Female breast cancers in both cohorts were
relatively more likely to receive surgery and systemic
and radiotherapy.
The relationships between receiving treatment and the
concurrent effects of stage at diagnosis and Indigenous
status are summarised in Table 3. Localised/not localised
stage at diagnosis did not predict receipt of any of the
treatment modes. However, being Aboriginal was associ-
ated with lower likelihood of receiving each treatment
mode. Indeed, Aboriginal cases had twice the odds of re-
ceiving none of the three treatment types compared to
Fig. 1 Linkage of hospital, medical benefits and pharmaceutical benefits
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Table 1 Modes of cancer treatment by Aboriginality, demographics and clinical characteristics
Aboriginal cohort Matched non-Indigenous cohort
N % Odds Ratio (unadjusted) 95%CI
Total 777 100.0% 777 100.0%
Matching variables
Age
<50 years 212 27.3% 190 24.5%
50-69 years 400 51.5% 408 52.5%
70+ years 165 21.2% 179 23.0%
Sex
Male 375 48.3% 375 48.3%
Female 402 51.7% 402 51.7%
Primary site
Colorectal (C18-C21) 77 9.9% 77 9.9%
Lung (C33-C34) 106 13.6% 106 13.6%
Breast (C50 & Female) 77 9.9% 77 9.9%
Cervix (C53) 24 3.1% 24 3.1%
All other sites 493 63.4% 493 63.4%
Socio-demographic and clinical variables
Geographically remote
No 606 78.0% 742 95.5% 1.00 Reference
Yes 171 22.0% 35 4.5% 5.98 4.09-8.74
Comorbid conditions (Elixhauser)
0-3 667 85.8% 742 95.5% 1.00 Reference
4+ 110 14.2% 35 4.5% 3.50 2.35-5.19
Summary stage at diagnosis
Localised 289 37.2% 390 50.2% 1.00 Reference
Regional 155 19.9% 132 17.0% 1.58 1.20-2.09
Distant/Unstageable 333 42.9% 255 32.8% 1.76 1.41-2.20
Treatment modality
Hospitalisation with primary diagnosis of cancer Received 617 79.4% 649 83.5% 0.76 0.59-0.98
Not received 160 20.6% 128 16.5% 1.00 Reference
Surgery Received 408 52.5% 488 62.8% 0.65 0.53-0.80
Not received 369 47.5% 289 37.2% 1.00 Reference
Systemic therapy Received 252 32.4% 334 43.0% 0.64 0.52-0.78
Not received 525 67.6% 443 57.0% 1.00 Reference
Radiotherapy Received 309 39.8% 360 46.3% 0.76 0.63-0.94
Not received 468 60.2% 417 53.7% 1.00 Reference
Each of surgery, systemic and radiotherapy Received 77 9.9% 140 18.0% 0.50 0.37-0.67
Not received 700 90.1% 637 82.0% 1.00 Reference
No surgery, systemic or radiotherapy Received 183 23.6% 110 14.2% 1.87 1.44-2.43
Not received 594 76.4% 667 85.8% 1.00 Reference
Vital statusb
Alive 220 28.3% 349 44.9% 1.00 Reference
Cancer death 461 59.3% 340 43.8% 2.15 1.73-2.68
Non-cancer death 96 12.4% 88 11.3% 1.73 1.24-2.42
aup to 2 months before and 13 months after month of diagnosis
bto censoring of observations at 31 December 2011
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their non-Indigenous contemporaries, OR = 2.09;
95%CI = 1.55–2.81 adjusted for stage at diagnosis.
Table 4 summarises the risk of cancer death using sub-
hazard ratios (SHR). Using cases among Aboriginal people
in non-remote settings as the reference group, Baseline
Model 1 indicates those cases experienced a lower risk of
cancer death than Aboriginal cases from geographically
remote areas, but significantly greater risk than non-
Indigenous cases from non-remote areas. Cancer stage
was highly predictive of the risk of cancer death, as was
the presence of 4 or more comorbid conditions [10].
With minor variations in SHRs, Indigenous status by
remoteness and 4 or more comorbidities contributed in
a similar manner to each of the subsequent models de-
rived. Stage at diagnosis also contributed a main effect
within each model. We found no further interactions be-
tween Indigenous status and stage at diagnosis or treat-
ment mode on the risk of cancer death.
However, interactions were found between stage at
diagnosis and the relevant treatment mode. For example,
in Model 2 cases with localised disease at diagnosis had
significantly lower risk of cancer death than those in the
reference category with more advanced stage of disease
and who also received surgery, SHR = 0.34; 95%CI =
0.25–0.47. In turn, cases who had more advanced disease
but did not receive surgery experienced twice the risk of
cancer death, SHR = 2.05; 95%CI = 1.48–2.85 compared
to those in the reference category. Similar effects were
observed in Model 3 (systemic therapy) with lower risk
of cancer death among cases with localised disease com-
pared to the reference group with advanced stage disease
and systemic treatment, SHR = 0.35; 95%CI = 0.25–0.48.
Those with more advanced disease cancer but did not
receive systemic therapy had higher risk of cancer death,
SHR = 1.65; 95%CI 1.25–2.19. Model 4 (radiotherapy)
also showed those with localised disease had lower risk
of cancer death than those with more advanced disease
and radiotherapy treatment, SHR = 0.26; 95%CI 0.19–
0.36. Among those with more advanced disease, the risk
of cancer death did not vary on the basis of receiving
radiotherapy.
Table 5 includes Model 5 (receipt of surgery and sys-
temic and radiotherapy). Again, localised disease at diag-
nosis was associated with lower risk of cancer death
compared to those with more advanced disease who re-
ceived all three treatment modalities, SHR = 0.38; 95%CI
0.24–0.58. In turn, others with advanced disease but who
did not receive all three forms of treatment had higher
average risk of cancer death, SHR = 1.62; 95%CI 1.09–
2.41. Model 6 focusses on the opposite scenario where
cases did not receive surgery, or systemic, or radiother-
apies. In this case, localised disease was associated with
lower risk when compared to the reference group of cases
with more advanced disease and who received any of the
three treatment modalities, SHR = 0.28; 95%CI 0.21–0.38.
Compared to the same reference group, those with more
advanced disease who did not receive any of the treatment
modalities experienced significantly higher risk of cancer
death. SHR = 1.82; 95%CI 1.26–2.63.
Model 7 simultaneously assessed reports of any of the
three treatment modalities among cases (Table 6). Over
and above the effects of Aboriginality, geographic remote-
ness and the number of comorbid conditions, the average
risk of cancer death varied significantly across groups on
the basis of stage at diagnosis and treatment received. With
regards to surgery, cases receiving surgery regardless of
their stage at diagnosis had lower risk (SHR= 0.56; 95%CI =
0.36–0.86) compared to the reference group of local stage
without surgery, SHR = 1, which was not statistically differ-
ent to those with more advanced disease who also did not
receive surgery (SHR= 1.12; 95%CI 0.66–1.89). With
regards to systemic therapy, cases with localised disease re-
gardless of therapy receipt had lower average risk (SHR =
0.50; 95%CI = 0.33–0.76) than the reference group with
more advanced disease and who received systemic therapy
(SHR= 1.00). Risk was comparatively higher when stage
was not localised and systemic therapy was not received,
SHR = 1.55; 95%CI = 1.15–2.08. With respect to radiother-
apy, cases with localised disease and no radiotherapy had
lower risk (SHR = 0.39; 95%CI = 0.22–0.67) compared to
those with more advanced disease and no radiotherapy,
SHR = 1.00, and those receiving radiotherapy regardless of
stage of disease (SHR= 1.11; 95%CI 0.82–1.50).
The lowest BIC values were observed for Model 2 (sur-
gery) and Model 3 (systemic therapies) which indicated
these as the best fitting, most parsimonious models. After
constraining cases to only include in-hospital principal
diagnosis of cancer within the treatment period, receipt of
surgery remained associated with lowest risk of cancer
death, SHR = 0.31; 95%CI = 0.22–0.46. Stratification using
broad primary site groupings were also tested with little
change to Model 2 and 3 parameters were observed. The
proportional hazard assumption was met in each of the re-
ported Models 1 to 7.
Figure 2 summarises the exposure to stage and treatment
categories associated with more and less risk of cancer
death. Relatively more Aboriginal cases were exposed to
higher risk of cancer death associated with living in geo-
graphically remote areas and having four or more comorbid
conditions. Fewer Aboriginal cases were exposed to stage
and treatment categories associated with less risk. For ex-
ample, fewer Aboriginal cases than non-Indigenous re-
ceived surgery (52.5% versus 62.8%). Conversely, Aboriginal
cases with advanced stage tumours that did not receive sur-
gery were comparatively more common (31.3% versus
22.0% of non-Indigenous cases) while 16% more Aboriginal
cases had more advanced tumours but did not receive sys-
temic therapies (41.1% versus 25.4%).
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Discussion
This population-based study of Aboriginal and non-
Indigenous cancer cases (matched by sex, age, year of
diagnosis and primary cancer site) affirmed that local-
ised cancers were associated with lowest risk of can-
cer death. When cancers with more advanced stages
were analysed, cases not receiving surgical treatment
were found to have twice the risk of cancer death as
cases having cancer surgery. Similarly, cases not re-
ceiving systemic therapies had a 65% higher risk of
cancer death compared to those receiving these treat-
ments. Radiotherapy appeared not to reduce the risk
of death; however, where all three treatments were re-
ported the risk of cancer death was reduced. Con-
versely, not receiving any of the three treatments was
associated with an 82% greater risk of cancer death
on average. No evidence was found of differential
treatment effects for Aboriginal and non-Indigenous
cases. What was clearly apparent though, was a wide-
spread lower treatment of Aboriginal cases relative to
their non-Indigenous matched contemporaries. Over
and above the effects of stage at diagnosis and cancer
treatment, being Aboriginal, living in remote locations
and having multiple comorbid conditions remained
associated with higher risk of cancer death.
The degree to which surgical and systemic treatments
reduced the risk of cancer death in cases with more ad-
vanced disease is consistent with other Australian popu-
lation studies. For example, receiving any cancer
treatment reduced the risk of cancer death among head
and neck cancer cases in Queensland by 20% [31] after
adjusting for socio-demographic influences, stage, and
comorbidities. In NSW, lung cancer surgery reduced risk
of cancer death by around three-quarters, but Aboriginal
and Torres Strait Island people faced 30% higher re-
sidual risk (SHR = 1.3) [28]. Also, the NT reported haz-
ard ratios in the order of 1.5 [29] among Aboriginal and
Torres Strait Islander cases with the most commonly di-
agnosed cancers after allowing for the effects of treat-
ment and this is equivalent to the sub-hazard risk of 1.6
observed in our study. For cancers overall, elevated risk
of cancer death among Aboriginal and Torres Strait Is-
lander cases persisted in a matched Queensland cohort
after allowance for area of residence, comorbidities, stage
and treatment (HR = 1.3) and occasions where no surgi-
cal treatment carried additional risk (HR = 1.9) [8]. Our
results differed in that reports of radiotherapy were asso-
ciated with reduced risk of cancer death in Queensland
(HR = 1.3 with no radiotherapy [8]) but this was not so
in the SA cohort. This finding is not without precedent
Table 5 Competing risk regression analyses for cancer survival among Aboriginal and matched non- Indigenous cohorts by discrete
treatment type, Models 5 and 6
Model 5 - surgery and systemic and
radiotherapies among cohorts




95% CI p > |z| Subhazard
Risk Ratio
95% CI p > |z|
Aboriginal x geographic remoteness non-Indigenous
not Remote 0.69 0.58–0.82 <0.001 0.70 0.59–0.83 <0.001
Remote 0.87 0.39–1.93 0.73 0.93 0.42–2.08 0.86
Aboriginal
not Remote 1.00 Reference 1.00 Reference
Remote 1.75 1.21–2.54 <0.01 1.64 1.12–2.40 <0.01
Comorbidity score (Elixhauser)
0–3 1.00 Reference 1.00 Reference
4+ 1.53 1.04–2.24 0.03 1.57 1.07–2.32 0.02
Stage x treatment modality
Local stage with/without treatment modality 0.38 0.24–0.58 <0.001
Not local stage with treatment modality 1.00 Reference
Not local stage without treatment modality 1.62 1.09–2.41 0.02
Stage x treatment modality
Local stage with/without any of treatment modalities 0.28 0.21–0.38 <0.001
Not local stage receiving none of the treatment modalities 1.82 1.26–2.63 <0.01
Not local stage receiving any of the treatment modalities 1.00 Reference
BIC 644.7 641.4
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[17] and may be influenced by whether radiotherapy was
intended to be curative, or palliative [57].
The lower exposure to the three treatment modes
among Aboriginal compared to non-Indigenous cases in
this study is consistent with the wider literature and
poses a risk to cancer survival [29, 33]. The disparities
ranged from lung cancers in WA where Aboriginal and
Torres Strait Islander cases were 36% less likely than
non-Indigenous cases to receive surgery [26, 27] to 14%
lower treatment rates in Queensland [30] where the
odds of receiving head and neck (20%) [31] and cervical
cancer (19%) [30] treatments were also reported. Within
similarly matched cohorts that considered all invasive
cancers, surgery was reportedly 24% less likely among
Aboriginal and Torres Strait Islander cases, as was
chemotherapy (20%) and radiotherapy (9%). Similarly,
we report greater odds (87%) of Aboriginal cases receiv-
ing no treatment compared to 38% in Queensland [9].
The differences in exposure to cancer treatment oc-
curred in Australia, a setting where health care is avail-
able to all residents and the health system monitors
performance to ensure equitable, timely access to ser-
vices by all [58, 59]. Nonetheless, we found differences
in access to healthcare exist. Firstly, Aboriginal cases up
to 24% less likely to be hospitalised with a primary diag-
nosis of cancer than their non-Indigenous contemporar-
ies. Secondly, once hospitalised, differences in utilisation
and quality of care [60, 61] were apparent and fewer
Aboriginal patients received surgery, systemic therapies
or radiotherapy. Effective, systematic responses are
needed to address these gaps in service access, utilisation
and quality. Attending to patient experience [62] is one
means of informing such responses while another is to
promote improved communication, cultural compe-
tency, safety and collaboration among patients and clini-
cians more generally. A further avenue to informing
responses would take advantage of electronic patient
care records by flagging relevant system inputs affecting
outputs and outcomes. For example, automatically flag-
ging the need for an interpreter is a useful input to assist
patient-centred exchanges with clinicians. Once treat-
ment pathways are initiated, documenting the influences
that affect uptake of those pathways, such as patient re-
fusal and/or clinical contra-indications, will inform on
what impediments to treatment uptake occur, where
they occur in the pathway and who they involve.
While our analysis was strengthened by an efficient
fixed effects design and allowance for competing risk from
Table 6 Competing risk regression analyses for cancer survival among Aboriginal and matched non- Indigenous cohorts by
concurrent treatment type
Model 7 - any treatment mode
Subhazard
Risk Ratio
95% CI p > |z|
Aboriginal x geographic remoteness non- Indigenous
not Remote 0.70 0.58–0.83 <0.001
Remote 0.77 0.37–1.61 0.49
Aboriginal
not Remote 1.00 Reference
Remote 1.53 1.02–2.28 0.04
Comorbidity score (Elixhauser)
0–3 1.00 Reference
4+ 1.72 1.16–2.54 <0.01
Stage x treatment modality
Any stage with surgery 0.56 0.36–0.86 <0.01
Local stage without surgery 1.00 Reference
Not local stage without surgery 1.12 0.66–1.89 0.68
Local stage with/without systemic therapy 0.50 0.33–0.76 <0.001
Not local stage with systemic therapy 1.00 Reference
Not local stage without systemic therapy 1.55 1.15–2.08 0.004
Local stage without radiotherapy 0.39 0.22–0.67 <0.001
Not local stage without radiotherapy 1.00 Reference
Any stage with radiotherapy 1.11 0.82–1.50 0.51
BIC 650.2
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non-cancer death, low case numbers limited stratification
by cancer sites. This highlights the desirability of pooling
analyses across jurisdictions to maximise statistical preci-
sion and improve generalisability for a relatively small
population with pressing needs. Nevertheless, the results
are consistent with other results in the international and
domestic literature using administrative hospital records.
The study also enabled a piloting of broader data coverage
by incorporating MBS and PBS with hospital admission
data as potentially sustainable sources of information on
cancer treatment in order to cover primary, community,
acute and tertiary care settings).
Not only was the extended data system within CanDAD
feasible, but it has enhanced our understanding of influ-
ences on the risk of cancer death among Aboriginal
people in South Australia by supplementing existing infor-
mation on likely effects of stage at diagnosis, geographic
remoteness and comorbidity to include the effects of, and
exposure to, cancer treatment types. Given the CanDAD
project’s governance includes Aboriginal community rep-
resentatives and South Australian Cancer Services, this in-
formation is directly available for system-wide cancer
control [63] and chronic disease [64] initiatives benefiting
Aboriginal and Torres Strait Islander people.
The results inform service planners on the lessor
treatment of Aboriginal than non-Indigenous cases
that heighten the risk of cancer death and negatively
influence cancer survivals. This is important evidence
for introducing corrective initiatives such as encour-
aging timely access and uptake of effective cancer
care in accordance with national treatment guidelines
[65] and maintaining monitoring activities within the
health system to assess effectiveness. For example, it
is feasible for CanDAD’s person-linked analyses to in-
form patient-centred enquiries and monitor exposure
to treatment and associated outcomes of care. These
data would complement those independently available
on quality of care and productivity in the health
system.
In using population cancer registry records as the basis
for CanDAD’s data system, we matched primary site
among Aboriginal and non-Indigenous cases on the
basis of 3-digit ICD-O-3 coding. It is possible the re-
ported differences in outcomes are influenced by differ-
ent distributions of tumour subtypes within those sites.
Given the non-Indigenous cases were drawn from a pool
of 219,234 diagnoses [1], it is feasible to pursue tumour
subtypes as an extra step in matching in future studies.
While the findings highlight the value of using available
administrative records, two limitations with their use also
emerged. Firstly, administrative practices saw less recording
of systemic therapies within hospital funding collections
from the 2007 financial year and an increased reliance on
PBS records for enumerating these therapies. By 2007,
Fig. 2 Exposure of risks associated with cancer death by cohort (Model 7)
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Aboriginal cases were more consistently linked to PBS re-
cords which enabled continuity in assessing exposure to
these therapies. A further limitation in evaluating exposure
to treatments more generally is that PBS data do not in-
form on whether the reported treatment course was com-
pleted, nor could we assess time to treatment or partition
treatments by curative intent. These issues raise further
R&D opportunities to incorporate relevant clinical informa-
tion into the CanDAD system with the aim of informing
continuous quality improvement activities encouraging
compliance with national guidelines and the uptake of opti-
mal cancer care pathways [65].
Conclusions
The fact that Aboriginal cancer patients were compara-
tively less likely to receive cancer treatment adds to dis-
parities in cancer death and exacerbate the disadvantages
that come from geographic remoteness, lack of cultural
awareness, advanced stage of disease and multiple co-
morbid conditions at diagnosis. A systemic response en-
suring earlier access to cancer care facilities and maximis-
ing the utilisation and quality of effective cancer
treatments should be actively pursued, to reduce the risk
of cancer death and improve survival after cancer diagno-
sis for Aboriginal and Torres Strait Islander people.
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